Rocky, I believe the potential with the diabetes r

Rocky, I believe the potential with the diabetes revenue stream is unlimited. I remember when Scrips reported $375K in compound pharmacy a year ago. Now we have a monthly average near $5M. This is what will happen with the diabetes business. A year from now we won't recognize it. I see this 500 patients easily growing by 500+ a month. Keep in mind though, with all these types of pharmacy supply programs there is monthly attrition rate, but the monthly total number of register patients will grow like compound (no pun intended) interest. What are witnessing is Mr. Bob Schneiderman's business model coming to life in a big way. I've been around for two years now and not to brag, I have a sizable position. I really don't care what any naysayer says, never have. SCRC is slowly building into a powerhouse. With Gregory FCA now on board now as SCRC's IR Team, the visibility and awareness we'll see created will drive SCRC's success beyond our greatest expectations. As I mentioned to another member of the CORE, every revenue stream trend line is pointing upward. We will soon break away from the .18's just like we did when we were in the .08-.09 range. No worries here, this stock is going to be historic.